Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.
Socioeconomic status shapes the gut microbiome in diverse U.S. population
Study using data from the FAMiLI project reveals socioeconomic status (SES) significantly impacts the gut microbiome’s diversity and composition across a diverse U.S. population, underscoring